Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants With Advanced Malignancies

  • STATUS
    Recruiting
  • days left to enroll
    47
  • participants needed
    126
  • sponsor
    ModernaTX, Inc.
Updated on 2 April 2021

Summary

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

Description

This is a Phase 1, open-label, multicenter, dose-escalation study of intratumoral injections of mRNA-2752 alone and in combination with intravenously administered immune checkpoint blockade therapy in participants with histologically confirmed advanced or metastatic solid tumor malignancies or lymphoma. The study consists of Dose Escalation and Dose Confirmation Parts, which will occur in Arm A and Arm B, followed by a Dose Expansion Part, which will occur in Arm B.

Participants in Arm A and in Arm B will be enrolled into the Dose Escalation Part and the doses of mRNA-2752 will be administered in a dose escalation regimen until a maximum tolerated dose (MTD) or a recommended dose for expansion (RDE) is identified. When the MTD/RDE is identified, participants with visceral lesions may be enrolled into the Dose Confirmation Part to confirm that the dose is also appropriate for this subgroup.

Once the MTD/RDE is identified in the Dose Escalation/Dose Confirmation Parts, participants in Arm B will be enrolled into the Dose-Expansion Part in order to assess the preliminary anti-tumor activity of mRNA-2752 in combination with durvalumab.

Following completion of 6 cycles of mRNA-2752, participants may continue with durvalumab alone until disease progression, unacceptable toxicity, or 24 months of treatment (total), whichever is sooner. If a participant is experiencing clinical benefit and it is in the participant's best interest, in the opinion of the Investigator, dosing of mRNA-2752 may continue beyond Cycle 6 (up to 24 total months of treatment) after approval from the Sponsor.

Details
Condition Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer, Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non-Hodgkin Lymphoma, and Urothelial Cancer
Treatment durvalumab, mRNA-2752, mRNA-2752 + durvalumab, mRNA-2752 + tremelimumab
Clinical Study IdentifierNCT03739931
SponsorModernaTX, Inc.
Last Modified on2 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Written informed consent prior to completing any study-specific procedure
Histologically confirmed advanced or metastatic disease with at least 1 measurable lesion as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Cheson 2016 criteria
Dose Escalation/Confirmation
Has disease progression after adequate standard of care therapies for metastatic disease that are known to confer clinical benefit, is intolerant to treatment, or refuses standard treatment (no limit to prior lines of therapy)
Dose Expansion
Group 1 Triple negative breast cancer: Must have objective evidence of disease progression during or following at least one prior line of therapy for metastatic or locally advanced disease
Group 2 Head and neck squamous cell carcinoma: Must have objective evidence of disease progression during or following platinum-containing chemotherapy as well as a programmed death -ligand 1 (PD-1/L1) therapy
Group 3 Non-Hodgkin's lymphoma: Must have objective evidence of disease progression following an anthracycline containing chemotherapy regimen, as well as an anti-CD20 monoclonal antibody unless CD20 is determined to be negative. Participants with transformed follicular lymphoma must have received prior chemotherapy for follicular lymphoma and subsequently have chemorefractory disease after transformation to diffuse large B-cell lymphoma (DLBCL)
Group 4 Urothelial cancer, first line: Must be cisplatin ineligible and PD-L1 negative
Group 5 Urothelial cancer: Must have objective evidence of disease progression during or following platinum-containing chemotherapy
Has a tumor lesion amenable to biopsy and must be willing to provide the baseline and on-treatment tumor biopsy samples if medically feasible. For participants with only 1 lesion amenable to injection, biopsy, and RECIST assessment, that lesion must be 2 centimeters (cm)
Eastern Cooperative Oncology Group (ECOG) performance status of 1
Has a body weight of >30 kilograms (kg)
Adequate hematological and biological function
Has evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal participants
Treatment Arm B: Thyroid-stimulating hormone within normal range

Exclusion Criteria

Has received prior systemic anti-cancer therapy including investigational agents within 28 days of the start of study treatment
Has current or prior use of immunosuppressive medication within 14 days before the first dose of study treatment
Has received prior radiotherapy within 14 days before the first dose of study treatment
Active central nervous system tumors or metastases
Has received a live vaccine within 30 days before the first dose of study treatment
Have major surgical procedures within 28 days or non-study-related minor procedures within 7 days before the first dose of study treatment
Requires active systemic anticoagulation at the time of intratumoral injection or biopsy
Active or prior documented autoimmune or inflammatory disorders
History of primary immunodeficiency, allogenic solid organ transplantation, or tuberculosis
Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and protocol defined laboratory values
Participants with Grade 2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician
Participants with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the Study Physician
Has active GI bleeding or hemoptysis or history of bleeding disorder
Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice), hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Participants positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA)
Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease (ILD), serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs, or compromise the ability of the participant to give written informed consent
Is a female participant who is pregnant or breastfeeding or male or female participant of reproductive potential who are not willing to employ effective birth control from screening to 120 days after the last dose of study treatment
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note